Organisation paid for research Program year 2025 Source: CMS Open Payments

South Broward Research

Neither a doctor nor a teaching hospital

Research payments

$1,589,515

544 payments

Through program year 2025, South Broward Research is reported as receiving $1,589,515 in research payments, across 544 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$95,300	57
2024	Research	$122,713	88
2023	Research	$547,121	209
2022	Research	$84,305	118
2021	Research	$285,603	20
2020	Research	$45,366	12
2019	Research	$409,107	40

Breakdown

Who paid Research payments · program years 2019–2025

Alnylam Pharmaceuticals Inc. $683,364 372 payments
Novo Nordisk AS $492,255 130 payments
Endo Pharmaceuticals Inc. $330,602 27 payments
AstraZeneca Pharmaceuticals LP $38,446 4 payments
Novartis Pharmaceuticals Corporation $25,602 5 payments
AstraZeneca UK Limited $12,677 2 payments
Pfizer Inc. $5,400 1 payment
Merck Sharp & Dohme Corporation $1,169 3 payments

Studies the money was for Research payments · program years 2019–2025

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) $539,452 315 payments
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products $330,602 27 payments
Nn1250-4419 $231,249 12 payments
Nn9535-4820 $99,685 85 payments
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) $86,041 26 payments
Nn9838-4433 $69,871 11 payments
Nn1250-4252 $66,865 6 payments
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) $57,872 31 payments
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia $51,123 6 payments
An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $25,390 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.